Fatma Akça
Fatma Akça has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Evren Ozcinar
Department of Cardiovascular Surgery, Ankara University, 06100 Ankara, Turkey
13 shared publications - Mehmet Cahit Sarıcaoğlu
Department of Cardiovascular Surgery, Ankara University, 06100 Ankara, Turkey
12 shared publications - Ali Fuat Karacuha
Department of Cardiovascular Surgery, Heart Center, Cebeci Hospitals, Ankara University School of Medicine, Ankara, Turkey
11 shared publications - Cagdas Baran
Ankara University, Turkey (Türkiye)
8 shared publications - Ahmet Kayan
Department of Cardiovascular Surgery, Heart Center, Cebeci Hospitals, Ankara University School of Medicine, 06340 Ankara, Turkey
7 shared publications - Nur Dikmen
Ankara University, Faculty of Medicine, Department of Cardiovascular Surgery, Heart Center, Ankara, Türkiye
7 shared publications
Latest Publications
- 30 September 2026
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 79 (3) , 292-298
Comparing Reintervention Factors in Acute Deep Vein Thrombosis and Post-Thrombotic Syndrome
Background: Acute iliofemoral deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS) are characterized by significant morbidity due to impaired venous drainage. Although technical success in endovascular interventions is increasing, the need for reintervention due to complications like stent thrombosis and restenosis remains the primary obstacle to long-term clinical success.Objective: This study aims to compare clinical characteristics and intraoperative findings requiring reintervention in acute DVT and PTS patients to optimize patient-specific follow-up and management strategies.Materials and Methods: We retrospectively evaluated 400 patients (184 Acute DVT, 216 PTS) who underwent iliofemoral venous stenting. A subgroup of 111 patients (51 Acute DVT, 60 PTS) undergoing reintervention for clinical or radiological failure was analyzed. Groups were statistically compared regarding demographics, reintervention indications, and intraoperative findings.Results: The 12-month primary patency rates were 72.5% for Acute DVT and 68.3% for PTS. Among those requiring reintervention, the PTS group had significantly higher rates of recent surgery/trauma (53.3% vs. 27.5%; p=0.010) and recurrent venous ulcers (48.3% vs. 23.5%; p=0.012). Intraoperatively, in-stent restenosis (ISR) was more frequent in the PTS group (66.7% vs. 47.1%; p=0.038). In the Acute DVT group, masked anatomical issues predominated, specifically contralateral outflow obstruction (15.7% vs. 3.3%; p=0.042) and untreated additional venous lesions (47.1% vs. 23.3%; p=0.015). Secondary patency rates remained high in both groups (90.2% and 85.1%).Conclusion: Reintervention etiologies for acute DVT and PTS differ significantly. Failure in PTS is associated with chronic ISR and ulcer recurrence, while missed anatomical lesions during the index procedure are decisive in acute DVT. Extensive anatomical mapping in acute cases and aggressive restenosis monitoring in PTS are critical for long-term success.
- 30 September 2026
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 79 (3) , 292-298
Comparing Reintervention Factors in Acute Deep Vein Thrombosis and Post-Thrombotic Syndrome
Background: Acute iliofemoral deep vein thrombosis (DVT) and post-thrombotic syndrome (PTS) are characterized by significant morbidity due to impaired venous drainage. Although technical success in endovascular interventions is increasing, the need for reintervention due to complications like stent thrombosis and restenosis remains the primary obstacle to long-term clinical success.Objective: This study aims to compare clinical characteristics and intraoperative findings requiring reintervention in acute DVT and PTS patients to optimize patient-specific follow-up and management strategies.Materials and Methods: We retrospectively evaluated 400 patients (184 Acute DVT, 216 PTS) who underwent iliofemoral venous stenting. A subgroup of 111 patients (51 Acute DVT, 60 PTS) undergoing reintervention for clinical or radiological failure was analyzed. Groups were statistically compared regarding demographics, reintervention indications, and intraoperative findings.Results: The 12-month primary patency rates were 72.5% for Acute DVT and 68.3% for PTS. Among those requiring reintervention, the PTS group had significantly higher rates of recent surgery/trauma (53.3% vs. 27.5%; p=0.010) and recurrent venous ulcers (48.3% vs. 23.5%; p=0.012). Intraoperatively, in-stent restenosis (ISR) was more frequent in the PTS group (66.7% vs. 47.1%; p=0.038). In the Acute DVT group, masked anatomical issues predominated, specifically contralateral outflow obstruction (15.7% vs. 3.3%; p=0.042) and untreated additional venous lesions (47.1% vs. 23.3%; p=0.015). Secondary patency rates remained high in both groups (90.2% and 85.1%).Conclusion: Reintervention etiologies for acute DVT and PTS differ significantly. Failure in PTS is associated with chronic ISR and ulcer recurrence, while missed anatomical lesions during the index procedure are decisive in acute DVT. Extensive anatomical mapping in acute cases and aggressive restenosis monitoring in PTS are critical for long-term success.
- Open Access
- 22 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 34 (3) , 284-291
Management of type II endoleak after EVAR: Risk assessment and surveillance
Management of type II endoleak after EVAR: Risk assessment and surveillance - Turkish Journal of Thoracic and Cardiovascular Surgery
- 22 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 34 (3) , 284-291
Open AccessManagement of type II endoleak after EVAR: Risk assessment and surveillance
Management of type II endoleak after EVAR: Risk assessment and surveillance - Turkish Journal of Thoracic and Cardiovascular Surgery
- 23 April 2026
- Published by SAGE Publications in Perfusion
- Vol. 41 (8) , 1401-1407
Modified Extracorporeal Circulation (mECC) for enhanced blood conservation in thoracoabdominal aortic surgery: A single-center experience
Background: Thoracoabdominal aortic aneurysm (TAAA) repair is associated with significant risks of blood loss and organ ischemia. This study evaluates the efficacy of a novel, modified Extracorporeal Circulation (mECC) circuit system designed to enhance blood conservation and selective organ perfusion during open TAAA repair. Methods: In this retrospective analysis, 7 patients underwent open thoracoabdominal aortic repair between January 2022 and October 2024 using a modified extracorporeal circulation system. The system incorporated integrated roller pumps for selective visceral and renal perfusion, a centrifugal pump, and an integrated autotransfusion system reservoir to optimize hemodynamic control and minimize allogeneic blood transfusion. Demographic data, intraoperative parameters, transfusion requirements, and postoperative outcomes were assessed. Results: The cohort consisted of 7 patients (57.1% male; mean age 54.4 ± 15.0 years). Crawford type I repair was performed in 71.4% of cases. The mean ECC duration was 104.4 ± 16.8 min, and mean aortic clamp time was 72.0 ± 18.5 min. The use of the integrated autotransfusion system resulted in reduced postoperative transfusion requirements and helped maintain hemoglobin levels. Postoperative complications included gastrointestinal events (42.9%), wound infections (42.9%), and spinal cord deficit (14.3%). Early in-hospital mortality was 14.3% (one patient, postoperative day 5). Kaplan-Meier analysis showed a 1-week survival rate of 85.7%, with all surviving patients remaining alive throughout the follow-up period. Conclusion: The modified ECC system with integrated roller pumps and cell-saver technology demonstrated favorable short-term outcomes and effective blood conservation in open TAAA repair. This reservoirless, isothermic, centrifugal circuit with peripheral cannulation may offer a safe and efficient alternative for complex aortic surgery. Larger, prospective studies with extended follow-up are warranted to confirm these findings and evaluate long-term durability.
- 23 April 2026
- Published by SAGE Publications in Perfusion
- Vol. 41 (8) , 1401-1407
Modified Extracorporeal Circulation (mECC) for enhanced blood conservation in thoracoabdominal aortic surgery: A single-center experience
Background: Thoracoabdominal aortic aneurysm (TAAA) repair is associated with significant risks of blood loss and organ ischemia. This study evaluates the efficacy of a novel, modified Extracorporeal Circulation (mECC) circuit system designed to enhance blood conservation and selective organ perfusion during open TAAA repair. Methods: In this retrospective analysis, 7 patients underwent open thoracoabdominal aortic repair between January 2022 and October 2024 using a modified extracorporeal circulation system. The system incorporated integrated roller pumps for selective visceral and renal perfusion, a centrifugal pump, and an integrated autotransfusion system reservoir to optimize hemodynamic control and minimize allogeneic blood transfusion. Demographic data, intraoperative parameters, transfusion requirements, and postoperative outcomes were assessed. Results: The cohort consisted of 7 patients (57.1% male; mean age 54.4 ± 15.0 years). Crawford type I repair was performed in 71.4% of cases. The mean ECC duration was 104.4 ± 16.8 min, and mean aortic clamp time was 72.0 ± 18.5 min. The use of the integrated autotransfusion system resulted in reduced postoperative transfusion requirements and helped maintain hemoglobin levels. Postoperative complications included gastrointestinal events (42.9%), wound infections (42.9%), and spinal cord deficit (14.3%). Early in-hospital mortality was 14.3% (one patient, postoperative day 5). Kaplan-Meier analysis showed a 1-week survival rate of 85.7%, with all surviving patients remaining alive throughout the follow-up period. Conclusion: The modified ECC system with integrated roller pumps and cell-saver technology demonstrated favorable short-term outcomes and effective blood conservation in open TAAA repair. This reservoirless, isothermic, centrifugal circuit with peripheral cannulation may offer a safe and efficient alternative for complex aortic surgery. Larger, prospective studies with extended follow-up are warranted to confirm these findings and evaluate long-term durability.
- Open Access
- 23 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3231
Mid-Term Clinical Outcomes of the Low-Profile Ankura™ Stent Graft System for Endovascular Aneurysm Repair
Background: To evaluate the real-world safety and mid-term clinical performance of the Ankura™ AAA Stent Graft System in patients undergoing endovascular aneurysm repair (EVAR). Materials and Methods: This prospective, multicenter PMCF study analyzed 100 patients with abdominal aortic aneurysms (AAAs). Patients were monitored for a mean duration of 2.26 years. Primary endpoints included 30-day major adverse events and 24-month treatment success. Statistical evaluation of risk factors for reintervention was performed using univariate logistic regression. Results: The study cohort was predominantly male (97%), with a mean age of 72.01 years. Hypertension (90%) and smoking (89%) were the most prevalent comorbidities. Regarding the primary endpoints, the 30-day MAE rate was 2%. During the overall follow-up (mean 2.26 years), the primary patency rate was 97%, demonstrating high structural integrity and sustained patency. However, the overall freedom from reintervention rate was 74%, corresponding to a 26% reintervention requirement and a 27% incidence of endoleak. Reinterventions were almost exclusively driven by these post-procedural morphological complications; specifically, 26 of the 27 patients with endoleaks required a secondary procedure. No preoperative clinical or anatomical parameters were identified as significant independent predictors of reintervention in the univariate analysis (p > 0.05). The overall mortality rate was 12%, with 0% aneurysm-related mortality. Conclusions: Mid-term success and reintervention after EVAR with the Ankura™ system are primarily driven by postoperative morphological complications, such as endoleaks, rather than baseline patient risk profiles. These findings underscore the critical importance of rigorous, lifelong radiological surveillance regardless of preoperative anatomical challenges.
- 23 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (9) , 3231
Open AccessMid-Term Clinical Outcomes of the Low-Profile Ankura™ Stent Graft System for Endovascular Aneurysm Repair
Background: To evaluate the real-world safety and mid-term clinical performance of the Ankura™ AAA Stent Graft System in patients undergoing endovascular aneurysm repair (EVAR). Materials and Methods: This prospective, multicenter PMCF study analyzed 100 patients with abdominal aortic aneurysms (AAAs). Patients were monitored for a mean duration of 2.26 years. Primary endpoints included 30-day major adverse events and 24-month treatment success. Statistical evaluation of risk factors for reintervention was performed using univariate logistic regression. Results: The study cohort was predominantly male (97%), with a mean age of 72.01 years. Hypertension (90%) and smoking (89%) were the most prevalent comorbidities. Regarding the primary endpoints, the 30-day MAE rate was 2%. During the overall follow-up (mean 2.26 years), the primary patency rate was 97%, demonstrating high structural integrity and sustained patency. However, the overall freedom from reintervention rate was 74%, corresponding to a 26% reintervention requirement and a 27% incidence of endoleak. Reinterventions were almost exclusively driven by these post-procedural morphological complications; specifically, 26 of the 27 patients with endoleaks required a secondary procedure. No preoperative clinical or anatomical parameters were identified as significant independent predictors of reintervention in the univariate analysis (p > 0.05). The overall mortality rate was 12%, with 0% aneurysm-related mortality. Conclusions: Mid-term success and reintervention after EVAR with the Ankura™ system are primarily driven by postoperative morphological complications, such as endoleaks, rather than baseline patient risk profiles. These findings underscore the critical importance of rigorous, lifelong radiological surveillance regardless of preoperative anatomical challenges.
- 23 March 2026
- Published by Academician Publishing
- p. 1499-1512
Kalp ve Damar Cerrahisinde Rejeneratif Tedaviler
Bu makalede, kardiyovasküler hastalıkların (KVH) günümüzdeki yaygınlığı ve mortaliteye katkısı göz önüne alınarak, rejeneratif tıp yaklaşımlarının kalp-damar cerrahisinde artan rolü ele alınmıştır. Özellikle mezenkimal kök hücreler (MSC), indüklenmiş pluripotent kök hücreler (iPSC) ve kardiyak progenitör hücreler gibi farklı hücre tiplerinin miyokard onarımı ve fonksiyonel iyileşme üzerindeki etkileri detaylandırılmıştır.Hücre bazlı ve hücresiz (ekzozom temelli) tedavi stratejileri, mevcut tedavilerin ötesinde doku rejenerasyonunu hedeflemektedir. Aynı zamanda gen düzenleme teknolojileri, doku mühendisliği ve ileri görüntüleme yöntemleriyle entegrasyonun, kişiselleştirilmiş ve daha etkili tedavi yaklaşımlarının geliştirilmesine katkı sağlayabileceği vurgulanmaktadır.
- 23 March 2026
- Published by Academician Publishing
- p. 1499-1512
Kalp ve Damar Cerrahisinde Rejeneratif Tedaviler
Bu makalede, kardiyovasküler hastalıkların (KVH) günümüzdeki yaygınlığı ve mortaliteye katkısı göz önüne alınarak, rejeneratif tıp yaklaşımlarının kalp-damar cerrahisinde artan rolü ele alınmıştır. Özellikle mezenkimal kök hücreler (MSC), indüklenmiş pluripotent kök hücreler (iPSC) ve kardiyak progenitör hücreler gibi farklı hücre tiplerinin miyokard onarımı ve fonksiyonel iyileşme üzerindeki etkileri detaylandırılmıştır.Hücre bazlı ve hücresiz (ekzozom temelli) tedavi stratejileri, mevcut tedavilerin ötesinde doku rejenerasyonunu hedeflemektedir. Aynı zamanda gen düzenleme teknolojileri, doku mühendisliği ve ileri görüntüleme yöntemleriyle entegrasyonun, kişiselleştirilmiş ve daha etkili tedavi yaklaşımlarının geliştirilmesine katkı sağlayabileceği vurgulanmaktadır.
- 23 March 2026
- Published by Academician Publishing
- p. 1401-1434
Total Yapay Kalp
Total yapay kalp (TAH) tedavisi, son yıllarda önemli ilerlemeler göstermiş olup, kısa süreli destek sağlayan büyük hacimli cihazlardan, uzun dönem destinasyon tedavi seçeneği olabilecek daha kompleks sistemlere doğru evrilmiştir. Gelecek çalışmaları, mevcut sınırlamaların — boyut, dayanıklılık, enfeksiyon riski ve yaşam kalitesi — aşılmasına, ayrıca pediatrik ve kompleks komorbiditeli hasta gruplarında kullanımın genişletilmesine odaklanmaktadır. Yeni mühendislik tasarımları cihaz boyutunu ve ağırlığını azaltmayı hedeflemekte, bu sayede çocuklar ve adölesanlar dâhil daha küçük vücut yapısına sahip erişkin hastalarda implantasyonu mümkün kılmaktadır. Gelişmiş biyomalzemeler ve biyouyumlu yüzey kaplamaları tromboembolik komplikasyonları, hemolizi ve enfeksiyonu azaltmayı amaçlamakta, biyoprotez tabanlı materyallerin kullanımı ise cihazın uzun dönem dayanıklılığını ve fizyolojik entegrasyonunu artırabilecek potansiyele sahiptir.Mevcut sistemlerin en önemli zorluklarından biri perkütan driveline enfeksiyonlarıdır. Bu sorunu azaltmak amacıyla transkütan enerji transfer sistemleri (TETS) geliştirilmektedir. Bu teknoloji, tam implant edilebilir cihazlara geçişte büyük bir adım olup enfeksiyon riskini azaltmakta ve mobiliteyi artırmaktadır. Ayrıca yeni nesil TAH’lar, sensör destekli akıllı kontrol üniteleri ile gerçek zamanlı hemodinamik adaptasyon sağlayarak doğal biventriküler fizyolojiyi daha etkin şekilde taklit edebilecektir. Yapay zekâ entegrasyonu, cihaz yönetiminde prediktif bakım, kişiselleştirilmiş pompa optimizasyonu ve olası cihaz arızası ya da hemodinamik bozulmaların erken tespitine olanak sağlayacaktır. Telemonitorizasyon sistemleri sayesinde sürekli ayaktan hasta takibi mümkün olacak, güvenlik artarken hastane yatışları ve sağlık maliyetleri azalacaktır.TAH geliştirmede en kritik ihtiyaçlardan biri pediatrik hastalara yönelik cihazların yaygınlaştırılmasıdır. Küçük boyutlu ve büyüme potansiyeline uygun cihazların yanı sıra, psikososyal destek, eğitim ve erişkine geçiş sürecinin yönetimi bu hasta grubunda uzun dönem sonuçların iyileştirilmesinde temel rol oynayacaktır. Gelecekte TAH, kalp-böbrek kombinasyonları gibi çoklu organ destek stratejileriyle de bütünleşebilir. Ayrıca pulmoner hipertansiyon ve sağ ventrikül afterload yönetimini optimize edebilecek adaptif modüllerin entegrasyonu da gündemdedir. Yeni nesil biyoprotez TAH ve rotary pompa tabanlı sistemler (örneğin BiVACOR) erken klinik çalışmalarda cesaret verici sonuçlar ortaya koymaktadır. INTERMACS, EUROMACS ve uluslararası TAH kayıtlarının genişlemesi, hasta seçimini optimize etmek, cihaz tasarımını geliştirmek ve düzenleyici onay süreçlerini hızlandırmak açısından kritik veriler sağlayacaktır. TAH tedavisinin geleceği, mühendislik inovasyonlarının kişiselleştirilmiş tıp ve multidisipliner bakım ile bütünleşmesine dayanmaktadır. Miniatürizasyon, enfeksiyonsuz enerji transferi, yapay zekâ destekli izlem ve pediatrik hasta grubuna genişleme, TAH’ın köprü tedavisinden uzun dönem destinasyon tedavisine dönüşmesini mümkün kılacaktır. Teknolojinin klinik deneyimle buluşmasıyla, gelecek nesil TAH platformlarının yalnızca sağkalımı uzatmakla kalmayıp, yaşam kalitesini de belirgin olarak artırması beklenmektedir.
- 23 March 2026
- Published by Academician Publishing
- p. 1401-1434
Total Yapay Kalp
Total yapay kalp (TAH) tedavisi, son yıllarda önemli ilerlemeler göstermiş olup, kısa süreli destek sağlayan büyük hacimli cihazlardan, uzun dönem destinasyon tedavi seçeneği olabilecek daha kompleks sistemlere doğru evrilmiştir. Gelecek çalışmaları, mevcut sınırlamaların — boyut, dayanıklılık, enfeksiyon riski ve yaşam kalitesi — aşılmasına, ayrıca pediatrik ve kompleks komorbiditeli hasta gruplarında kullanımın genişletilmesine odaklanmaktadır. Yeni mühendislik tasarımları cihaz boyutunu ve ağırlığını azaltmayı hedeflemekte, bu sayede çocuklar ve adölesanlar dâhil daha küçük vücut yapısına sahip erişkin hastalarda implantasyonu mümkün kılmaktadır. Gelişmiş biyomalzemeler ve biyouyumlu yüzey kaplamaları tromboembolik komplikasyonları, hemolizi ve enfeksiyonu azaltmayı amaçlamakta, biyoprotez tabanlı materyallerin kullanımı ise cihazın uzun dönem dayanıklılığını ve fizyolojik entegrasyonunu artırabilecek potansiyele sahiptir.Mevcut sistemlerin en önemli zorluklarından biri perkütan driveline enfeksiyonlarıdır. Bu sorunu azaltmak amacıyla transkütan enerji transfer sistemleri (TETS) geliştirilmektedir. Bu teknoloji, tam implant edilebilir cihazlara geçişte büyük bir adım olup enfeksiyon riskini azaltmakta ve mobiliteyi artırmaktadır. Ayrıca yeni nesil TAH’lar, sensör destekli akıllı kontrol üniteleri ile gerçek zamanlı hemodinamik adaptasyon sağlayarak doğal biventriküler fizyolojiyi daha etkin şekilde taklit edebilecektir. Yapay zekâ entegrasyonu, cihaz yönetiminde prediktif bakım, kişiselleştirilmiş pompa optimizasyonu ve olası cihaz arızası ya da hemodinamik bozulmaların erken tespitine olanak sağlayacaktır. Telemonitorizasyon sistemleri sayesinde sürekli ayaktan hasta takibi mümkün olacak, güvenlik artarken hastane yatışları ve sağlık maliyetleri azalacaktır.TAH geliştirmede en kritik ihtiyaçlardan biri pediatrik hastalara yönelik cihazların yaygınlaştırılmasıdır. Küçük boyutlu ve büyüme potansiyeline uygun cihazların yanı sıra, psikososyal destek, eğitim ve erişkine geçiş sürecinin yönetimi bu hasta grubunda uzun dönem sonuçların iyileştirilmesinde temel rol oynayacaktır. Gelecekte TAH, kalp-böbrek kombinasyonları gibi çoklu organ destek stratejileriyle de bütünleşebilir. Ayrıca pulmoner hipertansiyon ve sağ ventrikül afterload yönetimini optimize edebilecek adaptif modüllerin entegrasyonu da gündemdedir. Yeni nesil biyoprotez TAH ve rotary pompa tabanlı sistemler (örneğin BiVACOR) erken klinik çalışmalarda cesaret verici sonuçlar ortaya koymaktadır. INTERMACS, EUROMACS ve uluslararası TAH kayıtlarının genişlemesi, hasta seçimini optimize etmek, cihaz tasarımını geliştirmek ve düzenleyici onay süreçlerini hızlandırmak açısından kritik veriler sağlayacaktır. TAH tedavisinin geleceği, mühendislik inovasyonlarının kişiselleştirilmiş tıp ve multidisipliner bakım ile bütünleşmesine dayanmaktadır. Miniatürizasyon, enfeksiyonsuz enerji transferi, yapay zekâ destekli izlem ve pediatrik hasta grubuna genişleme, TAH’ın köprü tedavisinden uzun dönem destinasyon tedavisine dönüşmesini mümkün kılacaktır. Teknolojinin klinik deneyimle buluşmasıyla, gelecek nesil TAH platformlarının yalnızca sağkalımı uzatmakla kalmayıp, yaşam kalitesini de belirgin olarak artırması beklenmektedir.
- Open Access
- 4 March 2026
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 35 (1) , 14-22
Early outcomes of TEVAR: Spinal cord ischemia and reintervention rates in a single-center study
Aim: Thoracic endovascular aortic repair (TEVAR) is currently the preferred treatment for different pathologies of the thoracic aorta because of its technical advantages over open surgery. This single-center study analyzes early outcomes of TEVAR with a special focus on spinal cord ischemia (SCI) and reintervention rates and their relationship to patient and procedural variables. Material and Methods: Data were retrospectively collected from patients who underwent TEVAR between February 2012 and August 2023. Patients were classified by pathology type: thoracic aortic aneurysms (n=97, 66.4%), type B aortic dissections (n=28,19.2%), traumatic aortic injuries (n=12, 8.2%), and other pathologies (n=9, 6.2%). Primary outcomes included SCI and reintervention rates at one year post-procedure; secondary outcomes included stroke, upper extremity ischemia, and 30-day mortality. The statistical analysis used univariate and multivariate logistic regression models as well as Kaplan-Meier survival analyses with subgroup comparisons between elective and urgent cases.Results: A total of 146 patients were analyzed; 79.45% were male with an average age of 63.23±12.50 years. Of this population, 121 patients (82.9%) had elective procedures and 25 patients (17.2%) had urgent/emergent procedures; postoperative spinal cord ischemia developed in 11 patients (7.5%). The stroke rate was 13.7% (n=20).The 30-day mortality rate was significantly higher in patients undergoing urgent TEVAR compared to those undergoing elective procedures (32.0% vs. 13.2%, p=0.02). TEVAR-related reintervention was required within a year for 38 patients (26%).There are no independent predictors for spinal cord ischemia; however, the multivariate analysis shows that early reintervention has a strong association with diabetes mellitus (OR 3.2, 95% CI 1.3–7.8, p=0.01), history of smoking (OR 2.1, 95% CI 1.0–4.4, p=0.05), and lesions in distal zones (OR 2.4, 95% CI 1.1–5.2, p=0.03). Urgent cases showed a trend toward higher reintervention rates compared to elective procedures (40.0% vs. 23.1%, p=0.08). Conclusion: This study demonstrates that the risk of reintervention is increased in cases with a history of diabetes mellitus, smoking, and aortic pathologies located in the distal thoracic zone. Urgent procedures carry higher morbidity and mortality risks but should be confirmed by larger randomized multicenter studies.
- 4 March 2026
- Published by Damar Cerrahi Dergisi - Turkish Journal of Vascular Surgery in Turkish Journal of Vascular Surgery
- Vol. 35 (1) , 14-22
Open AccessEarly outcomes of TEVAR: Spinal cord ischemia and reintervention rates in a single-center study
Aim: Thoracic endovascular aortic repair (TEVAR) is currently the preferred treatment for different pathologies of the thoracic aorta because of its technical advantages over open surgery. This single-center study analyzes early outcomes of TEVAR with a special focus on spinal cord ischemia (SCI) and reintervention rates and their relationship to patient and procedural variables. Material and Methods: Data were retrospectively collected from patients who underwent TEVAR between February 2012 and August 2023. Patients were classified by pathology type: thoracic aortic aneurysms (n=97, 66.4%), type B aortic dissections (n=28,19.2%), traumatic aortic injuries (n=12, 8.2%), and other pathologies (n=9, 6.2%). Primary outcomes included SCI and reintervention rates at one year post-procedure; secondary outcomes included stroke, upper extremity ischemia, and 30-day mortality. The statistical analysis used univariate and multivariate logistic regression models as well as Kaplan-Meier survival analyses with subgroup comparisons between elective and urgent cases.Results: A total of 146 patients were analyzed; 79.45% were male with an average age of 63.23±12.50 years. Of this population, 121 patients (82.9%) had elective procedures and 25 patients (17.2%) had urgent/emergent procedures; postoperative spinal cord ischemia developed in 11 patients (7.5%). The stroke rate was 13.7% (n=20).The 30-day mortality rate was significantly higher in patients undergoing urgent TEVAR compared to those undergoing elective procedures (32.0% vs. 13.2%, p=0.02). TEVAR-related reintervention was required within a year for 38 patients (26%).There are no independent predictors for spinal cord ischemia; however, the multivariate analysis shows that early reintervention has a strong association with diabetes mellitus (OR 3.2, 95% CI 1.3–7.8, p=0.01), history of smoking (OR 2.1, 95% CI 1.0–4.4, p=0.05), and lesions in distal zones (OR 2.4, 95% CI 1.1–5.2, p=0.03). Urgent cases showed a trend toward higher reintervention rates compared to elective procedures (40.0% vs. 23.1%, p=0.08). Conclusion: This study demonstrates that the risk of reintervention is increased in cases with a history of diabetes mellitus, smoking, and aortic pathologies located in the distal thoracic zone. Urgent procedures carry higher morbidity and mortality risks but should be confirmed by larger randomized multicenter studies.
- 31 December 2025
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 78 (4) , 320-328
Predictors of Mortality Correlated with the SOFA Score in Pediatric VA-ECMO Patients
Background: The objective of this study was to analyze mortality predictors in pediatric VA-ECMO patients, correlating these predictors with the pediatric sequential organ failure assessment score (pSOFA). Aim: To enhance prognostic accuracy and support individualized clinical decision-making by evaluating the correlations between mortality predictors and pediatric sequential organ failure assessment (pSOFA) scores in pediatric VA-ECMO patients. Methods: We conducted a retrospective analysis of 80 consecutive pediatric VA-ECMO cases treated at our center between April 2018 and October 2021. Data collection included patient demographics, clinical features, pSOFA scores, and estimated mortality risks. Survival impacts and morbidity factors were also assessed. The overall decannulation and hospital discharge rates were recorded, with a particular focus on patients with congenital cardiac diseases and those experiencing postcardiotomy low cardiac output, who showed the highest survival rates. Results: Our analysis revealed that certain variables significantly influenced survival outcomes in pediatric VA-ECMO patients. These variables included age, weight, genetic disorders, inotropic support, inhaled nitric oxide (NO) usage, hemodiafiltration, duration of hospital stay, active cardiopulmonary resuscitation during cannulation, and various biochemical markers. Notably, the mean pSOFA scores were significantly lower in survivors compared to non-survivors (9.22 ± 1.43 vs. 13.06 ± 2.69, respectively). Overall decannulation and hospital discharge rates were 60% and 48.75%, respectively, with the highest rates observed in patients with congenital cardiac diseases and postcardiotomy low cardiac output (84.6% and 76.9%, respectively). Furthermore, several mortality predictors were identified, which correlated strongly with pSOFA scores. These predictors included the need for inotropic support, elevated levels of lactate and creatinine, a low protein/albumin ratio, and a low pH prior to cannulation. These findings underscore the critical importance of assessing the severity of organ failure and the overall clinical status when determining mortality risk in pediatric VA-ECMO patients. Conclusion: This study offers valuable insights into the association between pSOFA scores and mortality predictors in pediatric ECMO cases. The significant correlation between higher pSOFA scores and increased mortality highlights the necessity for comprehensive risk assessment and vigilant monitoring of clinical status to optimize patient outcomes. Our findings support the integration of pSOFA scores into routine clinical practice for more effective prognostication and individualized patient management in pediatric VA-ECMO.
- 31 December 2025
- Published by Ankara University in Ankara Üniversitesi Tıp Fakültesi Mecmuası
- Vol. 78 (4) , 320-328
Predictors of Mortality Correlated with the SOFA Score in Pediatric VA-ECMO Patients
Background: The objective of this study was to analyze mortality predictors in pediatric VA-ECMO patients, correlating these predictors with the pediatric sequential organ failure assessment score (pSOFA). Aim: To enhance prognostic accuracy and support individualized clinical decision-making by evaluating the correlations between mortality predictors and pediatric sequential organ failure assessment (pSOFA) scores in pediatric VA-ECMO patients. Methods: We conducted a retrospective analysis of 80 consecutive pediatric VA-ECMO cases treated at our center between April 2018 and October 2021. Data collection included patient demographics, clinical features, pSOFA scores, and estimated mortality risks. Survival impacts and morbidity factors were also assessed. The overall decannulation and hospital discharge rates were recorded, with a particular focus on patients with congenital cardiac diseases and those experiencing postcardiotomy low cardiac output, who showed the highest survival rates. Results: Our analysis revealed that certain variables significantly influenced survival outcomes in pediatric VA-ECMO patients. These variables included age, weight, genetic disorders, inotropic support, inhaled nitric oxide (NO) usage, hemodiafiltration, duration of hospital stay, active cardiopulmonary resuscitation during cannulation, and various biochemical markers. Notably, the mean pSOFA scores were significantly lower in survivors compared to non-survivors (9.22 ± 1.43 vs. 13.06 ± 2.69, respectively). Overall decannulation and hospital discharge rates were 60% and 48.75%, respectively, with the highest rates observed in patients with congenital cardiac diseases and postcardiotomy low cardiac output (84.6% and 76.9%, respectively). Furthermore, several mortality predictors were identified, which correlated strongly with pSOFA scores. These predictors included the need for inotropic support, elevated levels of lactate and creatinine, a low protein/albumin ratio, and a low pH prior to cannulation. These findings underscore the critical importance of assessing the severity of organ failure and the overall clinical status when determining mortality risk in pediatric VA-ECMO patients. Conclusion: This study offers valuable insights into the association between pSOFA scores and mortality predictors in pediatric ECMO cases. The significant correlation between higher pSOFA scores and increased mortality highlights the necessity for comprehensive risk assessment and vigilant monitoring of clinical status to optimize patient outcomes. Our findings support the integration of pSOFA scores into routine clinical practice for more effective prognostication and individualized patient management in pediatric VA-ECMO.
- Open Access
- 24 October 2025
- Published by MDPI AG in Preprints.org
Early Outcomes of TEVAR: Spinal Cord Ischemia and Reintervention Rates in a Single-Center Study
Objective: Thoracic endovascular aortic repair (TEVAR) has become the preferred treatment for various thoracic aortic pathologies due to its technical advantages over open surgery. This single-center study aims to analyze early outcomes of TEVAR, specifically focusing on spinal cord ischemia (SCI) and reintervention rates, while examining their relationships with patient and procedural variables. Methods: Data from patients who underwent TEVAR between February 2012 and August 2023 were retrospectively collected. Patients were categorized by pathology type: thoracic aortic aneurysms (n=97, 66.4%), type B aortic dissections (n=28,19.2%), traumatic aortic injuries (n=12, 8.2%), and other pathologies (n=9, 6.2%).Primary outcomes were spinal cord ischemia and 1-year reinterventions rates. Secondary outcomes included stroke, upper extremity ischemia, and 30-day mortality. Statistical analysis included univariate and multivariate logistic regression, Kaplan-Meier survival analysis, and subgroup comparisons between elective and urgent cases. Results: In the dataset of 146 patients, 116 (79.45%) were male, with an average age of 63.23 ± 12.50. Elective procedures were performed in 121 patients (82.9%) versus 25 urgent cases (17.2%). Among the complications, postoperative stroke was observed in 20 patients (13.7%), and upper extremity ischemia, likely due to occlusion of the subclavian artery, was observed in 10 patients (6.84%). Spinal cord ischemia was observed in 11 patients (7.5%), while TEVAR-related reintervention was required in 38 patients (26%). No significant relationship was found between SCI and the variables (p-value > 0.05); however, reintervention was required in 38 patients (26.0%) and was significantly associated with diabetes mellitus (OR 3.2, 95% CI 1.3-7.8, p=0.01), smoking history (OR 2.1, 95% CI 1.0-4.4, p=0.05), and distal zone lesions (OR 2.4,95% CI 1.1-5.2, p=0.03). Overall 30-day mortality was 17.1%. Urgent cases had higher 30-day mortality (32.0% vs. 13.2%, p=0.02) and reintervention rates (40.0% vs. 23.1%, p=0.08). Conclusions: This study demonstrates that the risk of reintervention is increased in cases with a history of diabetes mellitus, smoking, and aortic pathologies located in the distal thoracic zone. Urgent procedures carry higher morbidity and mortality risks. However, the current findings need to be supported by larger randomized multicenter studies.
- 24 October 2025
- Published by MDPI AG in Preprints.org
Open AccessEarly Outcomes of TEVAR: Spinal Cord Ischemia and Reintervention Rates in a Single-Center Study
Objective: Thoracic endovascular aortic repair (TEVAR) has become the preferred treatment for various thoracic aortic pathologies due to its technical advantages over open surgery. This single-center study aims to analyze early outcomes of TEVAR, specifically focusing on spinal cord ischemia (SCI) and reintervention rates, while examining their relationships with patient and procedural variables. Methods: Data from patients who underwent TEVAR between February 2012 and August 2023 were retrospectively collected. Patients were categorized by pathology type: thoracic aortic aneurysms (n=97, 66.4%), type B aortic dissections (n=28,19.2%), traumatic aortic injuries (n=12, 8.2%), and other pathologies (n=9, 6.2%).Primary outcomes were spinal cord ischemia and 1-year reinterventions rates. Secondary outcomes included stroke, upper extremity ischemia, and 30-day mortality. Statistical analysis included univariate and multivariate logistic regression, Kaplan-Meier survival analysis, and subgroup comparisons between elective and urgent cases. Results: In the dataset of 146 patients, 116 (79.45%) were male, with an average age of 63.23 ± 12.50. Elective procedures were performed in 121 patients (82.9%) versus 25 urgent cases (17.2%). Among the complications, postoperative stroke was observed in 20 patients (13.7%), and upper extremity ischemia, likely due to occlusion of the subclavian artery, was observed in 10 patients (6.84%). Spinal cord ischemia was observed in 11 patients (7.5%), while TEVAR-related reintervention was required in 38 patients (26%). No significant relationship was found between SCI and the variables (p-value > 0.05); however, reintervention was required in 38 patients (26.0%) and was significantly associated with diabetes mellitus (OR 3.2, 95% CI 1.3-7.8, p=0.01), smoking history (OR 2.1, 95% CI 1.0-4.4, p=0.05), and distal zone lesions (OR 2.4,95% CI 1.1-5.2, p=0.03). Overall 30-day mortality was 17.1%. Urgent cases had higher 30-day mortality (32.0% vs. 13.2%, p=0.02) and reintervention rates (40.0% vs. 23.1%, p=0.08). Conclusions: This study demonstrates that the risk of reintervention is increased in cases with a history of diabetes mellitus, smoking, and aortic pathologies located in the distal thoracic zone. Urgent procedures carry higher morbidity and mortality risks. However, the current findings need to be supported by larger randomized multicenter studies.